文献速递免疫规划卫生政策与健康促进

人类疱疹病毒疫苗研发中的T细胞免疫:研究进展与转化挑战

T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges.
PubMed 文献 · Vaccine · 2026-09-11

人类疱疹病毒广泛流行并建立终身潜伏,可间断或情境依赖地再激活,临床表现多样,使疫苗研发区别于多数急性感染。该综述采用「适应症-终点」框架,比较预防性与治疗性策略,分析抗原可及性、组织定位、宿主背景和终点选择如何影响细胞免疫原性向病毒学或临床获益的转化。

要点

  • 仅基于预防原发感染或中和抗体应答的评估不能涵盖所有免疫控制机制。
  • T细胞可识别感染或转化细胞、维持免疫监视并限制病毒复制、排毒、组织损伤或疾病进展。
  • T细胞导向策略正被研究用于治疗性疫苗、高危人群保护、再激活相关疾病预防及病毒相关肿瘤免疫治疗。

核心结论

  • 在涉及潜伏、再激活或病毒相关疾病的适应症中,仅评估预防原发感染或中和抗体应答不足以反映全部免疫控制机制。
  • T细胞导向策略正被研究用于治疗性疫苗、高危人群保护、再激活相关疾病预防及病毒相关肿瘤免疫治疗。
  • 抗原可及性、组织定位、宿主背景和终点选择影响可测细胞免疫原性是否转化为病毒学或临床获益。

研究设计与样本

  • 综述采用「适应症-终点」框架,比较预防性与治疗性策略。

主要发现

  • 人类疱疹病毒广泛流行、建立终身潜伏、可间断或情境依赖地再激活并导致多样临床表现。
  • T细胞可识别感染或转化细胞、维持免疫监视并限制病毒复制、排毒、组织损伤或疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human herpesviruses are widespread, establish lifelong latency, undergo intermittent or context-dependent reactivation, and cause diverse clinical manifestations. These features distinguish herpesvirus vaccine development from that for most acute infections. For indications involving latency, reactivation, or virus-associated disease, assessments based solely on the prevention of primary infection or on neutralizing-antibody responses do not capture all relevant mechanisms of immune control. Depending on the virus and indication, T cells may recognize infected or transformed cells, maintain immune surveillance, and limit viral replication, shedding, tissue injury, or disease progression. T-cell-directed strategies are therefore being investigated for therapeutic vaccination, protection of high-risk populations, prevention of reactivation-associated disease, and immunotherapy of virus-associated tumors. Using an indication-to-endpoint framework, this review compares preventive and therapeutic strategies and examines how antigen accessibility, tissue localization, host context, and endpoint selection influence whether measurable cellular immunogenicity translates into virological or clinical benefit across viruses and disease settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shao Y, Xie Z, Wang R, et al. T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges. Vaccine. 2026. PMID: 42727399. doi:10.1016/j.vaccine.2026.128992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。